• China’s drug regulator cleared HBM Holdings’ IND for HBM7004 in advanced solid tumors, enabling a China Phase 1 first-in-human study.
• HBM7004 is a B7H4xCD3 bispecific antibody developed on the HBICE platform.
• The clearance follows earlier FDA authorization to start a Phase 1 trial in the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260818-12288508), on August 18, 2026, and is solely responsible for the information contained therein.